# Inventiva completes enrollment of its 1,009-patient phase 3 NATiV3 trial of lanifibranor in MASH

Canonical page: https://technooptimist.io/stories/inventiva-completes-enrollment-of-its-1-009-patient-phase-3-nativ3-1ad9d765
Date: 1 Apr 2025
About: [Inventiva](https://technooptimist.io/companies/inventiva.md) · [Lanifibranor](https://technooptimist.io/biotech/lanifibranor.md)
Original source: https://www.biospace.com/press-releases/inventiva-announces-completion-of-enrollment-in-the-phase-3-nativ3-clinical-trial-of-lanifibranor-in-patients-with-mash-and-advanced-fibrosis

Inventiva finished randomising patients into NATiV3, the phase 3 trial of its daily pan-PPAR pill in MASH with moderate to advanced liver scarring. The main cohort beat its target of 969 with 1,009 patients, and an exploratory cohort added 410. The trial tests two doses against placebo for 72 weeks, with biopsy-based endpoints.

## Key facts

- Main cohort 1,009 (target 969); exploratory cohort 410 (target 350).
- Doses: 800 mg and 1,200 mg once daily vs placebo.
- Endpoints: MASH resolution and at least one-stage fibrosis improvement after 72 weeks.
- Lanifibranor holds FDA Breakthrough Therapy and Fast Track designations.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.